Table 2:
Distribution of Serum Biomarkers of AMP Participants by HIV Infection Status
| Cohort |
||||
|---|---|---|---|---|
| Serum Biomarkers | Perinatally HIV- Infected (PHIV) (N=246) Median (IQR) |
Perinatally HIV- exposed Uninfected (PHEU) (N=156) Median (IQR) |
Total (N=402) |
P value* |
| Cardiac Biomarkers | ||||
| NT-proBNP (pg/mL) | 32.55 (13.70, 62.70) | 35.75 (18.00, 60.45) | 34.30 (15.10, 61.00) | 0.33 |
| Abnormal NT-proBNP (>100 pg/mL) | 27 (11%) | 23 (15%) | 50 (12%) | 0.28 |
| Hs-cTnT (pg/mL)** | 3 (3, 3) | 3 (3, 3) | 3 (3, 3) | <0.001 |
| Abnormal hs-cTnT (Above the limit of detection at >3 pg/mL) | 54 (22%) | 10 (6%) | 64 (16%) | <0.001 |
| Inflammatory Biomarkers | ||||
| hsCRP (mg/L) | 0.40 (0.20, 1.30) | 0.50 (0.20, 1.60) | 0.45 (0.20, 1.40) | 0.98 |
| Abnormal hsCRP (>1 mg/L) | 71 (29%) | 48 (31%) | 119 (30%) | 0.74 |
| TNF-α (pg/mL) | 7.70 (4.90, 11.10) | 6.90 (4.70, 9.80) | 7.33 (4.80, 10.60) | 0.20 |
| sTNF-RII (pg/mL) | 2,920 (2,254, 4,057) | 2,612 (2,210, 3,200) | 2,728 (2,236, 3,701) | 0.004 |
| IL-10 (pg/mL) | 2.90 (1.70, 4.80) | 3.00 (1.60, 4.45) | 2.90 (1.60, 4.80) | 0.80 |
| IL-1 (pg/mL) | 0.77 (0.50, 1.50) | 1.00 (0.50, 1.80) | 0.80 (0.50, 1.60) | 0.026 |
| IL-8 (pg/mL) | 6.66 (4.43, 21.90) | 7.10 (4.50, 13.80) | 6.80 (4.47, 19.40) | 0.78 |
| IL-18 (pg/mL) | 260 (196, 356) | 215 (176, 281) | 241 (187, 321) | <0.001 |
| IL-6 (pg/mL) | 1.00 (0.50, 2.10) | 1.16 (0.60, 2.20) | 1.00 (0.60, 2.15) | 0.13 |
*
P value by Wilcoxon rank sum test.
**
hs-cTnT values were not measured for 6 participants (4 PHIV, 2 PHEU).
IQR=interquartile range (25th, 75th percentiles); NT-proBNP=N-terminal-pro-brain natriuretic peptide; hsCRP=high-sensitivity C-reactive protein; hs-cTnT=high-sensitivity cardiac troponin-T; TNF-α=tumor necrosis factor-α; sTNF RII=soluble tumor necrosis factor receptor Type II; IL=interleukin.